Navigation Links
Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
Date:8/10/2009

PALO ALTO, Calif., Aug. 10, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial, run in centers in Australia and New Zealand, will investigate the antiviral effect of clemizole monotherapy in the absence of interferon.

CLEAN-1 will evaluate the safety and antiviral activity of clemizole, a first generation antihistamine, in 28 days of oral therapy in treatment-naive patients infected with HCV genotypes 1 and 2. This direct antiviral study represents an important first step in evaluating the therapeutic potential of inhibiting a new target in HCV -- small molecule inhibition of the interaction between NS4B and HCV-RNA that is required for HCV replication.

"This proof of concept study is an important first step in our comprehensive development strategy for clemizole and newly discovered NS4B-RNA binding inhibitors for the treatment of HCV," said David Cory, President and CEO of Eiger. "Inhibiting the NS4B-RNA interaction represents an exciting new approach toward developing interferon-free, virus-specific agents to treat HCV."

Eiger BioPharmaceuticals recently announced the acquisition of the exclusive license to this novel HCV technology, discovered in the labs of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues. Clemizole targets a non-structural protein found in the HCV genome, NS4B, which binds to HCV-RNA and is required for virus replication. Disrupting the function of this protein represents a new approach to treat HCV infection and may be associated with less drug resistance than polymerase and protease inhibitors in development.

About NS4B and Clemiz
'/>"/>

SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
2. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
3. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
5. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
8. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
11. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... release its second quarter 2014 financial results for the period ... market close. PDL,s management will host a conference call and ... the financial results.  A slide presentation relating to the call ... website. Conference Call Details To access the ...
(Date:7/28/2014)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Results and Highlights Conference CallWhen:Monday, August 4 at 10:30 ... on the Internet. Simply log onto our website listed ... live event, a replay of the webcast will be ... ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting ...
(Date:7/28/2014)...  ProteinSimple announced today that it has launched a ... allows users to detect all proteins separated in the ... can analyze proteins without the need for an antibody.  ... analysis as we know it today. First, the Simple Western ... messy gels, no transfer tanks, no blots, no imaging ...
Breaking Medicine Technology:PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2ProteinSimple Says "Never Run a Gel Again!" 2
... /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. ... traded biopharmaceutical company developing human vaccines for diseases ... infectious agents, announced today that Chuck Panozzo, founder ... joined the GeoVax Labs awareness campaign as an ...
... Boston Scientific Corporation (NYSE: BSX ) ... quality of life outcomes, based on one-year data from ... percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(R) Paclitaxel-Eluting ... hospital days during the first year after treatment compared ...
Cached Medicine Technology:Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 2Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 3Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 5
(Date:7/28/2014)... (PRWEB) July 28, 2014 Mahendra Trivedi, ... hosted the Trivedi Online Workshop ‘Consciousness is Power’ on ... (EST). During this workshop, participants from all over the ... of making a deeper connection to their inner guidance ... participants explored the various advantages of raising consciousness and ...
(Date:7/28/2014)... Scientists in Japan have completed initial tests ... for the asbestos cancer mesothelioma. Surviving Mesothelioma has just ... here to read it now. , Researchers in ... Graduate School of Medicine say a new test for ... the old test. , “Particularly for the epithelioid ...
(Date:7/28/2014)... Neenah, Wisconsin (PRWEB) July 28, 2014 ... management business process outsourcing (BPO) for Fortune 500 brands, ... 2,500 jobs across its locations in Wisconsin, California, Florida ... will be based at its Neenah campus. , A ... clients, which have seasonal ramp-ups that require additional staffing ...
(Date:7/28/2014)... Community Health Center of Snohomish County (CHC), a non-profit ... released an article designed to educate patients about the ... 1983, the health center has a strong focus on ... barriers to obtaining high quality yet affordable healthcare services. ... click here: http://www.chcsno.org/locations.ashx?p=1099 , The article begins ...
(Date:7/28/2014)... The research found that most of ... best, with each subsequent bite being less satisfying than ... serve to sabotage the meal. , "People have ... realizing the effect," Baba Shiv, the study's author, said ... if we needed one. You actually take more pleasure ...
Breaking Medicine News(10 mins):Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 3Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:Alta Resources To Fill Approximately 600 Positions In Neenah 2Health News:Alta Resources To Fill Approximately 600 Positions In Neenah 3Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 2Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 3Health News:Large Portions Can Decrease Food Enjoyment, SlimPlate Weight Loss System Puts Focus On Portion Control 2Health News:Large Portions Can Decrease Food Enjoyment, SlimPlate Weight Loss System Puts Focus On Portion Control 3
... overall incidence of cancer and death due to cancer dropped ... United States, according to a report published in the November ... Cancer Institute . , Each year the American Cancer Society, ... Institute, and the North American Association of Central Cancer Registries ...
... Outbreak in WestMiddlesexAreaSchool District Sickens 32 , ... to a pertussis outbreak in the West Middlesex Area School ... Luther Low Elementary School and West Middlesex Junior/Senior High School ... , The tetanus/diphtheria/pertussis vaccine was given ...
... expert says , , TUESDAY, Nov. 25 (HealthDay News) -- ... tiny pumps implanted in people with failing hearts -- ... , However, the finding should not affect current medical ... replaced by second- and third-generation VADS that are far ...
... Health Issues , , WASHINGTON, ... will present its Conference on Health Disparities on January 30-31, ... This conference is part of the NABJ Media Institute,s professional ... number of health disparities in the black community and to ...
... and CEO, Melissa Murer Corrigan, RPh, has received the 2008 ... the National Organization for Competency Assurance (NOCA). The award recognizes ... programs or practices for the field of certification and licensure. ... ...
... Nov. 25 Stop and think. That is what,Las Vegas-based ... are asking Las Vegas to do this World AIDS Day. ... the day with a,fundraising dinner to re-launch a new educational ... For the past three ...
Cached Medicine News:Health News:Limited Value Found for First-Generation Heart Pumps 2Health News:Limited Value Found for First-Generation Heart Pumps 3Health News:Black Journalists to Host Conference on Health Disparities 2Health News:Melissa Murer Corrigan Receives Prestigious NOCA Leadership Award 2Health News:Melissa Murer Corrigan Receives Prestigious NOCA Leadership Award 3Health News:Las Vegas Charities Mark World AIDS Day by Asking Residents to 'THINK' 2
Small, removable blades, length 178 mm, (7"). Function: tissue retracting....
Toothed Pituitary Rongeurs, 12 300 mm....
Ferris Smith Rongeurs, 12 overall length 300 mm....
The Skull Pins are inserted into the receptacles of the Skull Clamp and fixate the head during surgery....
Medicine Products: